×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EQ – equillium, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EQ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/18
08:30 am
eq
Equillium to Participate in the 38th Annual Roth Conference
Low
Report
Equillium to Participate in the 38th Annual Roth Conference
3/13
08:36 am
eq
Equillium Announces $35 Million Financing with RA Capital Management [Yahoo! Finance]
Medium
Report
Equillium Announces $35 Million Financing with RA Capital Management [Yahoo! Finance]
3/13
08:00 am
eq
Equillium Announces $35 Million Financing with RA Capital Management
High
Report
Equillium Announces $35 Million Financing with RA Capital Management
2/28
05:57 am
eq
Equillium (EQ) was upgraded by Zacks Research to "hold".
Medium
Report
Equillium (EQ) was upgraded by Zacks Research to "hold".
2/25
08:48 am
eq
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference [Yahoo! Finance]
2/25
08:30 am
eq
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
Medium
Report
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
2/25
08:00 am
eq
Equillium (EQ) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.
Medium
Report
Equillium (EQ) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.
2/2
04:05 pm
eq
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
04:13 pm
eq
Form SCHEDULE 13G Equillium, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
Medium
Report
Form SCHEDULE 13G Equillium, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
3/16
06:53 pm
eq
Form 4 Equillium, Inc. For: Mar 13 Filed by: Zedelmayer Christine
Medium
Report
Form 4 Equillium, Inc. For: Mar 13 Filed by: Zedelmayer Christine
3/13
04:09 pm
eq
Form 144 Equillium, Inc. Filed by: Zedelmayer Christine
Medium
Report
Form 144 Equillium, Inc. Filed by: Zedelmayer Christine
3/13
08:15 am
eq
Form 8-K Equillium, Inc. For: Mar 11
Medium
Report
Form 8-K Equillium, Inc. For: Mar 11
3/11
08:25 pm
eq
Form 4/A Equillium, Inc. For: Feb 19 Filed by: Zedelmayer Christine
Low
Report
Form 4/A Equillium, Inc. For: Feb 19 Filed by: Zedelmayer Christine
3/11
08:11 pm
eq
Form 4 Equillium, Inc. For: Mar 09 Filed by: Zedelmayer Christine
Low
Report
Form 4 Equillium, Inc. For: Mar 09 Filed by: Zedelmayer Christine
3/9
04:08 pm
eq
Form 144 Equillium, Inc. Filed by: Zedelmayer Christine
Low
Report
Form 144 Equillium, Inc. Filed by: Zedelmayer Christine
3/3
03:22 pm
eq
Form 4 Equillium, Inc. For: Feb 19 Filed by: Zedelmayer Christine
Medium
Report
Form 4 Equillium, Inc. For: Feb 19 Filed by: Zedelmayer Christine
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
33.1%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
12/9 Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis 17.3%
11/13 Form S-3 Equillium, Inc. 13.4%
1/24 Biocon Ltd. ADR (BCNQY) CEO Siddharth Mittal on Q3 2020 Results - Earnings Call Transcript [Seeking Alpha] 8.7%
1/2 Form 3 Equillium, Inc. For: Jan 01 Filed by: Zedelmayer Christine 7.6%
8/12 Q2/2019 6/30/2019 EPS -0.350 ZacksConsensus -0.340 ActVsEst (0.010) - Miss 5.6%
12/12 Form 4 Equillium, Inc. For: Dec 10 Filed by: Connelly Stephen 5.3%
3/30 Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital 4.2%
11/7 Equillium to Present at Investor Conferences in November 2019 4.0%
8/15 Equillium (NYSE: EQ) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.00 price target on the stock. 3.6%
TOP News Decliners
12/31
Equillium (NYSE: EQ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
-19.3%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
8/5 Form 4 Equillium, Inc. For: Aug 01 Filed by: Keyes Jason A -17.3%
12/23 Hedge Funds Are Dumping Equillium, Inc. (EQ) [Yahoo! Finance News] -12.4%
11/15 Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health -8.1%
12/10 MDB, GNW among premarket gainer [Seeking Alpha] -8.0%
11/12 Q3/2019 9/30/2019 EPS -0.350 ZacksConsensus N/A ActVsEst N/A - N/A -7.5%
2/27 Equillium Strengthens Leadership Team with Key Appointments -5.5%
9/17 Equillium to Host Business Update Call on October 1, 2019 -4.7%
1/29 Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR -4.4%
3/26 Q4/2019 12/31/2019 EPS -0.440 ZacksConsensus -0.400 ActVsEst (0.040) - Miss -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: